Viatris Pacira Deal: $1.65 Billion Bet on Non-Opioid Pain Relief
Viatris will buy Pacira BioSciences for $36.50 a share in cash, about $1.65 billion, in a bet on non-opioid pain drugs. Here is how the deal…
Viatris will buy Pacira BioSciences for $36.50 a share in cash, about $1.65 billion, in a bet on non-opioid pain drugs. Here is how the deal…
Translated automatically by Google. Names and quotes may not be perfect.
Voices come from your phone or computer. The ones marked ★ sound the most natural.
Look
Now playing